Home cancer injections: a new hope for myeloma patients?

NCT ID NCT06015542

Recruiting now Disease control Sponsor: Thomas Lund Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether people with relapsed multiple myeloma can safely inject the drug elranatamab at home instead of going to a clinic. Twenty participants will learn to self-administer the injections and track side effects like fever, nerve issues, and infections. The goal is to see if home treatment is safe, practical, and improves quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elranatamab (a drug injected under the skin)
What this could lead to: If successful, this could allow multiple myeloma patients to safely receive treatment at home, improving convenience and quality of life.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to all patients. Self-administration carries risks of side effects like cytokine release syndrome or infections, which may be harder to manage at home.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Department of Heamatology
RECRUITING

Vejle, 7100, Denmark
Odense University Hospital
RECRUITING

Odense, 5000, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.